4.4 Article

Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy

Journal

IMMUNITY INFLAMMATION AND DISEASE
Volume 10, Issue 3, Pages -

Publisher

WILEY
DOI: 10.1002/iid3.571

Keywords

allergic rhinitis; gene expression; mucosa; nasal spray

Categories

Funding

  1. Mylan N.V.

Ask authors/readers for more resources

The study compared the effects of different drug treatments on immune gene expression profiles, and found that the combination spray AZE/FP was significantly more effective in reducing allergic rhinitis symptoms and did not lead to extensive local immune suppression.
Background: The combination of the antihistamine azelastine (AZE) with the corticosteroid fluticasone propionate (FP) in a single spray, has been reported to be significantly more effective at reducing allergic rhinitis (AR) symptoms than treatment with either corticosteroid or antihistamine monotherapy. However, the biological basis for enhanced symptom relief is not known. This study aimed to compare gene expression profiles (760 immune genes, performed with the NanoString nCounter) from peripheral blood and nasal brushing/lavage lysate samples in response to nasal spray treatment. Methods: Moderate/severe persistent dust mite AR sufferers received either AZE (125 mu g/spray) nasal spray (n = 16), FP (50 mu g/spray) nasal spray (n = 14) or combination spray AZE/FP (125 mu g AZE and 50 mu g FP/spray) (n = 14) for 7 days, twice daily. Self-reported symptom questionnaires were completed daily for the study duration. Gene expression analysis (760 immune genes) was performed with the NanoString n-Counter on purified RNA from peripheral blood and nasal brushing/lavage lysate samples. Results: In nasal samples, 206 genes were significantly differentially expressed following FP treatment; 182 genes downregulated (-2.57 to -0.45 Log2 fold change [FC]), 24 genes upregulated (0.49-1.40 Log2 FC). In response to AZE/FP, only 16 genes were significantly differentially expressed; 10 genes downregulated (-1.53 to -0.58 Log2 FC), six genes upregulated (1.07-1.62 Log2 FC). Following AZE treatment only five genes were significantly differentially expressed; one gene downregulated (-1.68 Log2 FC), four genes upregulated (0.59-1.19 Log2 FC). Immune gene changes in peripheral blood samples following treatment were minimal. AR symptoms improved under all treatments, but improvements were less pronounced following AZE treatment. Conclusion: AZE/FP, FP, and AZE had diverse effects on immune gene expression profiles in nasal mucosa samples. The moderate number of genes modulated by AZE/FP indicates alternative pathways in reducing AR symptoms whilst avoiding extensive local immune suppression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available